Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.74%
As of Thursday, September 17, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.74%, which has investors questioning if this is right time to sell.Jenna Brashear
Stock Evaluator: Verrica Pharmaceuticals Inc. (VRCA)
Verrica Pharmaceuticals Inc. VRCA
$4.45
-0.20
-4.30%
September 18, 2026 4:00:00 PM
EST
Volume: 113,179
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Commentary & Analysis
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.90%
As of Wednesday, September 02, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.90%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.13%
As of Friday, August 28, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.13%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.34%
As of Wednesday, August 19, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.34%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 9.51%
As of Friday, August 07, Verrica Pharmaceuticals Inc.’s VRCA share price has dipped by 9.51%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $76.4 | $586.4 | 19% |
|
| Shares Out (Mil) | 21.3 | 43.1 | 31% |
|
| Institutional Ownership | 42.7% | 83.7% | 18% |
|
| Float (Mil) | 7.9 | 45.1 | 16% |
|
| Beta | 1.50 | 0.73 | 83% |
|
| Avg Daily Volume (000s) | 56 | 331 | 29% |
|
| Price Change (52-week) |
0.9% | 63.2% | 51% |
|
| Growth | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 16.0% | (1.4%) | 66% |
|
| EPS (5yr) | 37.1% | 15.1% | 87 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.8%) | (15.0%) | 15% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 4 | |
| Current EPS | ($0.520) | ($1.965) | ($1.478) | |
| Month Ago EPS | ($0.537) | ($2.007) | ($1.473) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.427) | ($1.733) | ($1.243) | |
| Year/Year Chg | (16.1%) | 17.0% | (29.9%) | |
| Financials | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $30 | $317 | 16% |
|
| Net Income (TTM) (Mil) | ($31) | ($11) | 20% |
|
| EPS (TTM) | ($1.883) | ($0.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($6) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 16% |
|
| Enterprise Value (Q1) (Mil) | $81 | $515 | 19% |
|
| Valuation | VRCA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 17.80 | 2.51 | 95% |
|
| P/E | na | 17.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 37.7% | 69.4% | 46% |
|
| Net Margin | (102.8%) | 2.5% | 7% |
|
| ROA | (83.0%) | (22.4%) | 7% |
|
| ROE | 473.3% | (21.8%) | 99% |
|
| Liabilities to Assets | 88.0% | 32.4% | 82% |
|
| F-Score | 6 | 3 | 67% |
|
Verrica Pharmaceuticals Inc. did not pass any screens on 9/18/2026.
